Multi-institutional Study of Carbon-ion Radiotherapy for Locally Advanced Pancreatic Cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 Pancreas

• Published in: International journal of radiation oncology, biology, physics Vol. 101; no. 5; pp. 1212 - 1221
• Main Authors: Kawashiro, Shohei, Yamada, Shigeru, Okamoto, Masahiko, Ohno, Tatsuya, Nakano, Takashi, Shinoto, Makoto, Shioyama, Yoshiyuki, Nemoto, Kenji, Isozaki, Yuka, Tsuji, Hiroshi, Kamada, Tadashi
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2018
• Subjects: Adult; Aged; Aged, 80 and over; CARBON IONS; Dose Fractionation, Radiation; Female; Heavy Ion Radiotherapy - methods; Humans; ION BEAMS; JAPAN; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; NEOPLASMS; PANCREAS; Pancreas - radiation effects; Pancreatic Neoplasms - radiotherapy; Patient Safety; Radiation Oncology - methods; RADIOLOGY AND NUCLEAR MEDICINE; RADIOTHERAPY; Retrospective Studies; SAFETY; Time Factors; Treatment Outcome; Japan
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/j.ijrobp.2018.04.057

The aim of this multi-institutional study was to evaluate the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for locally advanced pancreatic cancer (LAPC). Patients with LAPC treated with C-ion RT from April 2012 to December 2014 at 3 institutions were retrospectively analyzed. Patients with pathologically-confirmed invasive ductal adenocarcinoma of the pancreas were eligible. The prescribed dose was 52.8 Gy (relative biological effectiveness weighted absorbed dose; RBE) or 55.2 Gy (RBE) in 12 fractions. Overall survival (OS), distant metastasis-free survival (DMFS), local recurrence (LR), and toxicity were evaluated. In total, 72 patients were included in this study. Tumors in the head of the pancreas were seen in 30 patients (42%), while those in the body or tail of the pancreas were seen in 42 patients (58%). Fifty-six patients (78%) received concurrent chemotherapy. The OS rates were 73% (95% confidence interval [CI], 62%-84%) at 1 year, and 46% (95% CI, 31%-61%) at 2 years with a median OS of 21.5 months (95% CI, 11.8-31.2 months). The 1- and 2-year DMFS rates were 41% (95% CI, 29%-52%) and 28% (95% CI, 16%-40%), respectively. The 1- and 2-year cumulative incidences of LR were 16% (95% CI, 9%-26%) and 24% (95% CI, 14%-36%), respectively. Nineteen patients (26%) experienced acute grade 3 or 4 hematological toxicities. Two patients (3%) had grade 3 anorexia. Late gastrointestinal (GI) grade 3 toxicity was observed in 1 patient (1%). No patients developed late grade 4 or 5 toxicity. The first multi-institutional analysis of C-ion RT for LAPC indicated relatively favorable outcomes with limited toxicities, especially for tumors not in close proximity to GI tract.